RDRC Approved Drug Master File in Place (Currently Available in PET Formulary)
| Agent | Target |
|---|---|
| [11C]PBR-28 | TSPO, aka peripheral benzodiazepine receptor |
| [11C]DASB | serotonin transporter |
| [11C]CUMI-101 | serotonin 5-HT1A receptor agonist |
| [11C]DTBZ | VMAT2 vesicular monoamine transporter |
| [11C]CFT | dopamine transporter |
| [11C]FLB457 | dopamine D2/D3 receptor |
| [11C]raclopride | (dopamine D2/D3 receptor) |
| [11C]NPA | dopamine D2 receptor agonist |
| [11C]NOP-1A | nociceptin/orphanin FQ peptide receptor |
| [11C]UCB-J | SV2A |
| [11C]PIB | β-amyloid |
| [18F]FDG | glucose metabolism |
| [18F]MK 6240 | τ-Requires prospective protocol approval by Cerveau |
| [18F]BCPP-EF | mitochondrial complex I-Use requires prospective protocol approval by Hamamatsu) |
| [11C]ER-176 | TSPO, aka peripheral benzodiazepine receptor |
RDRC Approved Drug Master File in Place (Not currently Available in PET Formulary)
Available upon Request- Contact Head of Radiochemistry
| Agent | Target |
|---|---|
| [15O]H2O | perfusion |
| [15O]O2 | oxygen metabolism |
| [13N]Ammonia | myocardial blood flow |
| [18F]FMISO | hypoxia |
| [11C]3-O-methylglucose | glucose transport |
| [11C]PMP | acetylcholinesterase substrate |
| [18F]FLT | thymidine kinase substrate |
| [18F]ML10 | apoptosis |
| [11C]flumazenil | central benzodiazepine receptor |
| [11C]PK-11195 | TSPO, aka peripheral benzodiazepine receptor |
| [carbonyl-11C]WAY-100635 | serotonin 5-HT1A receptor |
| [11C]fallypride | dopamine D2/D3 receptor |
| [18F]altanserin | serotonin 5-HT2A receptor |
| [11C]IMA107 | PDE10A |
| [68Ga]PRGD2 | integrin αVβ3 |
| [11C]McN5652X and W | serotonin transporter |
| [18F]FNOS | inducible nitric oxide synthase |
FDA-approved IND Chemistry, Manufacturing and Control Documentation
| Agent | Target |
|---|---|
| [18F]AV1451 | τ-Use requires prospective protocol approval by Lily/Avid |
| [11C]ABP 688 | metabotropic glutamate receptor subtype 5-IND inactive |
| [18F]FDOPA | AADC substrate-Sponsored study Voyager Therapeutics |
| [11C]PIB | β-amyloid |
| [18F]flutemetamol | β-amyloid-IND inactive |
| [18F]2'FPiB | β-amyloid-IND inactive |
| [18F]2’F-BiP** | β-amyloid-IND inactive |
| (**[18F]-2’F-4’-HO-6-MeNHBT) | |
| [18F]FAraG | Activated T cells- Use requires prospective protocol approval by CellSight, LLC. |
| [18F]BMS-986192 | PD-L1 expression- Use requires prospective protocol approval by Bristol-Myers Squibb |
| [64Cu]LLP2A | Very Late Antigen-4 (VLA-4) |
FDA IND Chemistry, Manufacturing and Control Documentation (in process)
| Agent | Target |
|---|